The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Sfibp - These boards have always been that way. It will never change.
In todays market one of the biggest risk factors is a companies ability to raise funds. With this now in place, and at only 6% above the oversubscribed raise, it would appear to be underpinning the current market cap. An entry at these levels for new entrants is compelling.
When it comes to a new rig, with funding in place the company is now better positioned to secure a rig. Let’s wait and see what the company comes up with as todays entry price more than compensates for any delay.
Many economists are expecting a global downturn in 2023 as economic conditions worsen in the face of tighter liquidity, in turn the availability of rigs should improve. But I expect them to secure a rig in a timely fashion regardless of market conditions.
Disgruntled sellers looking for a lower entry point that won’t come. They will kick around until their newly raised capital from todays sale is redeployed elsewhere and they lose interest in HE1.
Next update will come soon to satisfy market, and low and behold all will be forgotten. Seen this play out time and time again.
With the placing oversubscribed you can see that many are still taking opportunity of these lower prices.
Without the negative nellies this opportunity wouldn’t exist. Once they get bored I fully expect this to recover to 7p prior to an update on the next rig. Secured with cash in hand.
Going into rig discussions with funding in place makes it far easier to secure a rig.
An MOU was appropriate to secure funding, now funding is in place it doubles from here just on mobilization.
Todays project update has presented new and serious existing investors with a fantastic opportunity to purchase shares at or near to the placing price.
Fully funded and geologically spud ready, get us that rig and let the fun begin.
Can’t wait and thank you Invictious energy for this entry point.
I think those that don’t travel are missing the point.
1. Requirements are for a PCR test not lateral flow.
2. For the UK to renegade on most recent comms to the point that they now require testing is further confirmation that their is a bigger issue afoot (new variant of concern)
Valueinv. With all due respect, it’s that opinion that has led to an underwhelming valuation prior to this decision by comparison to the first fda cycle.
Not only that the two tech’s are at completely different stages within their respective developed industry cycles.
It is reasonable to suggest that with approx 50% of the market cap represented by cash leaving corporate core assets valued at just over £16m, with a turnover of a few million and decent news flow soon to kick in.
This is purely a case of poor liquidity through a lack of volume/interest. Let the news flow tell the story. It’s been a slow start and it’s now time for management to deliver on its admission document.
RUA submitted its (510k) today. Also reported revenue of less than a quarter of Genincode, and only has £4.7m as of March, compared to Genincode £17m cash pile.
With a market cap equal to Genincode’s and up 6.6% on the day, targeting a smaller market opportunity. Explain the market cap with £12/13m cash differential and tell me that Genincode is not significantly undervalued
Transfer of stock perhaps into sipp or between Isa’s
But definitely some nice buys at a great price today. Our time is coming.
Over the coming months, we will target the following key deliverables:
-- Develop Cardio inCode (R) launch program with Eversana for introduction to US market in 2022
-- Continue to progress our Breakthrough Device Designation discussions with FDA for Cardio inCode (R)
-- File Cardio inCode (R) de-novo submission for US regulatory approval with the FDA
-- Establish CPT coding for Cardio inCode (R) and commence CMS payer and reimbursement discussions
-- Complete RB&H set-up and commissioning for Lipid inCode (R) hypercholesterolemia testing
-- Complete Indiana University and New York Presbyterian collaborations as flagship facilities for introduction of Cardio inCode (R) and Thrombo inCode (R)
-- Appoint US CLIA (Clinical Laboratory Improvement Amendments) authorized testing facility
-- Complete and publish NHS Hypercholesterolemia study for Lipid inCode (R)
-- Advance RB&H Lipid inCode hypercholesterolemia product with NHS, AHSN's and Private payer networks
-- Complete our first COVID-19 Thrombo inCode (R) evaluation study for genetic predisposition to thrombosis
This is why I am happy to be of the journey. It’s a transformational period, and I have skipped all the initial trials that cost money and time. Roll on commercialization.
This valuation takes a discount to NPV into consideration when considering where it stands in its commercial pathway. Also a projected earnings multiple based on a peer comparison that would ordinarily see its peers valued in the billions.
Plenty of scope for upwards revision to TP
'@Stifel initiate coverage for @GenIncode with a BUY rating - "With US launch planned for 2022 and potential for sales to reach $225m by 2028E, we see significant upside to the shares." Target price 175p #GENI
A good starting point would be to refer to other IPO’s within the last several months to identify a particular pattern which in my opinion happens on a fairly regular basis.
From IPO you often see those that invested in the company when it was privately listed taking some profits as they are likely to have seen significant returns on capital following an IPO. It will then all depend on the commercial story, the news flow and broker forecasts.
For me the commercial pathway and news flow v market cap is what is so compelling about Geni and why within the next few weeks we should see a significant uplift in interest.
To date I have found all the answers to the questions I have been looking for, perseverance and persistence has assisted me in that endeavor. But I have no doubt that this upcoming investor meets will shine a new light on areas of the company that we haven’t yet considered.
Today’s broker note is a short term target only, but on the basis of a peer comparison when accessing valuation over the next 12 months should the main commercial milestones results in a positive outcome. It is clear to see the full potential here.
Cenkos initiates coverage at 73p in short term with significant upside potential.
De Novo application is imminent as we enter into a prior of significant news flow that will see additional coverage/revisions and an escalation in volume that will see this share rerate.
Personally, I expect 145p by end of tax year.
* Uk launch of Lipincode also expected Q3, should be a very busy end to the quarter and year end.
Agreed with a number of key catalysts coming in the short term including interim results, de novo submission for CardioIncode, paper on both Uk collaboration and the Covid study which should see the EUA submission for ThromboInCode.
All this and more to look forward to.
Broker note from Stifel, a highly encouraging write up
CardioIncode is the only test that has been validated with an evidence base of over 70,000 individuals from different population groups. This evidence base was subject to research and development costs of over €50m, with clinical trials and such like being performed over a 10 year period. With an enhanced and balanced patent portfolio, CardioIncode should be subject to a de novo application during the course of Q3 with ongoing discussions with the FDA only possible if it ultimately met the de novo criteria. With the average de novo timeline to a decision taking 241 days, the lead up to 2H 22” could IMO lead to a performance similar to that of AGL from 40p as news flow drives sentiment/volume.
CardioIncode test analyzes 170 genetic variants from blood or saliva, and when used in conjunction with SITAB. The Company’s SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information and, using algorithms and artificial intelligence, assesses a patient’s risk of a cardiovascular event. It reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format.
It is also the only available genetic test for the assessment of cardiovascular risk that measures the patient’s genetic load and integrates it into the current risk profile of the patient.
Ultimately it is the evidence base and simplification of a genetic platform and integration of a sample to answer program (SITAB) to practitioners. This platform is well supported by the key opinion leaders within the sector that has created a barrier to entry of sorts, such as investment (€50m), time (10 years) and in turn an evidence base that is unrivaled on a like for like basis.
I understand a newly IPO’d company going through a period of extreme growth evidenced by the considerable commercialization plan over the next 12 months on multiple levels could justify a slower implementation plan of an investor relation department that isn’t otherwise walbrook. I can certainly forgive, overlook this in favor of such an exciting opportunity ahead.
It is this lack of understanding that has presented what is a modest valuation at best and presents a significant opportunity for those that are happy to do a deep dive into the companies prospects. Hope this helps.
My understanding is that we have multiple examples of Plc’s that have been listed for a material period of time which has allowed them to evolve their shareholder register over time. You may find that the share price has fluctuated through phased trials and respective dilution. In my opinion the difference with Geni and what the market has not become aware of to date is that Geni in the main is at a period of material shareholder value creation. To be approaching the FDA application this quarter having missed the €50m euros of development over time means that new shareholders are jumping the cue by comparison to the typical aim story, and it is this that hasn’t been fairly valued by the market to date.
In a nut shell, to have already received CE approval and made application for UK approval has somewhat derisked the opportunity, with an outcome from the FDA device designation also further derisking this opportunity. Those that participated in the raise would of done their due diligence to also consider this risk.
I can see this achieving 500% returns from here prior to the FDA decision. It’s been incredibly hard to maintain strict portfolio allocation discipline given the fantastic risk v reward opportunity here.